
Given subcutaneously every 3 months, cemdisiran (Livsayis) is indicated for adults with AChR antibody–positive gMG and requires REMS enrollment.
This study discusses various treatments for multiple sclerosis, with a specific focus on alternative strategies like CCSVI.
The video from The National Multiple Sclerosis Society discusses various treatments for multiple sclerosis, with a specific focus on alternative strategies like CCSVI.





